Stocks & Investing
Thu, September 26, 2024
[ 12:00 AM ] - WOPRAI
Tue, September 10, 2024
[ 12:00 AM ] - WOPRAI
Mon, June 17, 2024
Mon, May 20, 2024
[ 12:00 AM ] - WOPRAI
Fri, May 10, 2024
[ 12:00 AM ] - WOPRAI
Fri, April 12, 2024
[ 12:00 AM ] - WOPRAI
Mon, February 26, 2024
[ 12:00 AM ] - WOPRAI
Thu, January 11, 2024
Wed, December 20, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 29, 2023
[ 12:00 AM ] - WOPRAI
Wed, June 14, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
Tue, December 6, 2022
[ 12:00 AM ] - WOPRAI
Thu, October 6, 2022
[ 12:00 AM ] - WOPRAI
Tue, August 16, 2022
Fri, February 11, 2022
[ 12:00 AM ] - WOPRAI
Tue, January 6, 2015 Julian Harrison Maintained (VRDN) at Strong Buy with Increased Target to $61 on, Sep 26th, 2024
Julian Harrison of BTIG, Maintained "Viridian Therapeutics, Inc." (VRDN) at Strong Buy with Increased Target from $56 to $61 on, Sep 26th, 2024.
Julian has made no other calls on VRDN in the last 4 months.
There are 7 other peers that have a rating on VRDN. Out of the 7 peers that are also analyzing VRDN, 0 agree with Julian's Rating of Hold.
These are the ratings of the 7 analyists that currently disagree with Julian
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $44 on, Thursday, September 19th, 2024
- Richard Law of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $31 on, Thursday, September 12th, 2024
- Serge Belanger of "Needham" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, September 11th, 2024
- Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $27 on, Tuesday, September 10th, 2024
- Leland Gershell of "Oppenheimer" Reiterated at Buy with Decreased Target to $28 on, Monday, August 12th, 2024
- Laura Chico of "Wedbush" Reiterated at Buy and Held Target at $42 on, Monday, July 29th, 2024
- Andy Chen of "Wolfe Research" Initiated at Buy on, Tuesday, June 11th, 2024
